Annual Report 2023

Financial Report

15Cash and cash equivalents

For the purpose of the Consolidated Statement of Cash Flows, cash and cash equivalents comprise the following as at 31 December of each year:

kEUR	2023	2022

Cash and cash equivalents	95,706	37,528
Balance as at 31 December	95,706	37,528

As described in Note 19, PolyPeptide Group AG signed a revolving credit facility agreement with three banks during 2023. In addition, it secured a short-term credit facility from its main shareholder, Draupnir Holding B.V.

For the purpose of the Consolidated Statement of Cash Flows, changes in liabilities arising from financing activities for the years were as follows:

kEUR	Non-current interest-bearing loans and borrowings	Current interest-bearing loans and borrowings	Non-current other financial liabilities	Lease liabilities	Current other financial liabilities

Balance as at 1 January 2023	–	–	9,410	21,218	1,096

Cash flows	49,087	40,000	–	-4,550	-1,096

Non-cash flows
New lease liabilities	–	–	–	6,445	–
Remeasurements	–	–	1,232	58	–
Accrued interest	–	1,253	597	627	–
Government loans waived	–	–	–	–	–
Transfer from non-current to current	–	–	-1,227	–	1,227
Currency exchange differences	–	–	-119	-476	–
Balance as 31 December 2023	49,087	41,253	9,893	23,322	1,227

kEUR	Non-current interest bearing loans and borrowings	Current interest-bearing loans and borrowings	Non-current other financial liabilities	Lease liabilities	Current other financial liabilities

Balance as at 1 January 2022	–	–	10,302	18,005	1,145

Cash flows			–	-3,254	-1,145

Non-cash flows
New lease liabilities	–	–	–	3,203	–
Remeasurements	–	–	523	1,907	–
Accrued interest	–	–	611	559	–
Transfer from non-current to current	–	–	-1,096	–	1,096
Currency exchange differences	–	–	-929	798	–
Balance as 31 December 2022	–	–	9,410	21,218	1,096